4sc Ag

4sc Discovery Gmbh

Immunic Ag

Laboratorios Del Dr. Esteve S.a.

Stefan Tasler

Johann Leban

Mirko Zaja

Carine Chevrier

Ilga Krimmelbein

Daniel Vitt

Wael Saeb

Roland Baumgartner

Juergen Kraus

Michael Kubbutat

Martin Lang

Christoph Schaechtele

Jakob Felding

Hella Kohlhof

Andreas Wuzik

Frank Totzke

Rolf Krauss

Thomas Herz

Bernd Kramer

Kristina Wolf

Manfred Gröppel

Katharina Aulinger-Fuchs

Andrea Aschenbrenner

Peter Ney

Rolf Andreas Muhler

Manfred Groppel

Jürgen Kraus

Rolf Andreas MÜHLER

Jordi-Ramon Quintana-Ruiz

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein Ar, Z and Y are as described herein and R1 is a group of the structure wherein n is 0 or 1; R2 is H, deuterium or methyl; R3 is methyl, trifluoromethyl, ethyl, or taken with R2 together forms a cyclopropyl group, or R3 forms a methylene bridge to the carbon atom marked *, which are suitable for the treatment of autoimmune diseases and chronic inflammation. 

IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation

Compounds of formula (II) or a pharmaceutically acceptable salt or solvate thereof, the medical uses thereof for diseases or medical conditions where the inhibition of the voltage-gated potassium channel Kv1.3 is beneficial, and methods for their preparation.

KV1.3 inhibitors and their medical application

Kv1.3 inhibitors and their medical application

The present invention relates to a compound of the general formula (III) or a salt, solvate or prodrug thereof, as well as medical uses involving them,  wherein A, A, A, A, A, A, Y, Rand Rare as defined herein, and methods for producing such compounds.

Kv1.3 inhibitors and their medical applications

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents. 

IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation

This invention relates to novel aryloxypropanolamines. The invention also relates to the pharmaceutically acceptable salts and solvates containing said compounds, methods for the preparation thereof and to respective synthetic intermediates. Said compounds have agonistic activity at &#x3b2;3 adrenergic receptors and are useful for treatment of ailments influenced by activation of &#x3b2;3 adrenergic receptors.

Aryloxypropanolamines, methods of preparation therof and use of aryloxypropanolamines as medicaments

The present invention relates to compounds of the general formulas (I), (Ia) and (II) and salts and physiologically functional derivatives thereof, whereinthe substituents &#x2014;Y are attached to the 5- or 6-position of the benzazole.

Benzazole analogues and uses thereof

The present invention relates to N-heteroaryl-benzazole-2,(5 or 6)-diamine derivatives and compositions thereof as protein kinase inhibitors for the treatment of e.g. cancer.

The present invention relates to compounds of the general formula (II) and salts and physiologically functional derivatives thereof, for the use as a medicament.

Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents

The present invention provides a compound capable of binding to the ubiquinone binding site of DHODH which contains a non-aromatic ring system as a core structure, a group capable of interacting with structural elements of subsite 2 or 3 of the ubiquinone binding site of DHODH and a group capable of interacting hydrophobically with structural elements of subsite 1 of the ubiquinone binding site of DHODH. Furthermore, the present invention provides a compound capable of binding to the ubiquinone binding site of DHODH which contains an aromatic ring system as a core structure, a group capable of interacting with residues His 56 and/or Tyr 356 of subsite 3 of the ubiquinone binding site of DHODH and a group capable of interacting hydrophobically with structural elements of subsite 1 of the ubiquinone binding site of DHODH.

Method of identifying inhibitors of DHODH

Growing community of inventors

Seefeld, Germany

Stefan Tasler